IMPACT OF DOCETAXEL (D) – BASED CHEMOTHERAPY ON QUALITY OF LIFE (QOL) OF PATIENTS (PTS) WITH HORMONE- REFRACTORY PROSTATE CANCER (HRPC): RESULTS FROM A RANDOMISED PHASE II TRIAL WITH D ± ESTRAMUSTINE (E)

Phase II trial of anti-idiotypic p53 peptides (Pentrys) plus granulocyte-macrophage colony-stimulating factor in patients with hormone-refractory prostate cancer

Asia-Pacific Journal of Clinical Oncology ◽

10.1111/j.1743-7563.2007.00101.x ◽

2007 ◽

Vol 3 (3) ◽

pp. 148-155

Author(s):

Ian D DAVIS ◽

Guy TONER ◽

Adam BROAD ◽

Louise M CAMPANO ◽

Mark ROSENTHAL

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Colony Stimulating Factor ◽

Macrophage Colony Stimulating Factor ◽

Hormone Refractory ◽

Macrophage Colony ◽

Stimulating Factor ◽

P53 Peptides

Baseline quality of life measured with the EORTC QLQ-C30 helps to select a subset of ‘good prognosis’ metastatic hormone refractory prostate cancer patients

European Journal of Cancer ◽

10.1016/s0959-8049(01)81290-9 ◽

2001 ◽

Vol 37 ◽

pp. S218 ◽

Cited By ~ 3

Author(s):

L. Collette ◽

S.D. Fossa ◽

G.O.N. Oosterhof ◽

W. Albrecht ◽

G. van Andel ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Cancer Patients ◽

Good Prognosis ◽

Eortc Qlq C30 ◽

Hormone Refractory ◽

Eortc Qlq

50 QUALITY OF LIFE IN A RANDOMIZED PLACEBO-CONTROLLED PHASE II TRIAL OF THE SPECIFIC ENDOTHELIN A RECEPTOR ANTAGONIST ZD4054 IN PAIN-FREE OR MILDLY SYMPTOMATIC PATIENTS WITH METASTATIC HORMONE-RESISTANT PROSTATE CANCER

European Urology Supplements ◽

10.1016/s1569-9056(09)60058-0 ◽

2009 ◽

Vol 8 (4) ◽

pp. 133 ◽

Cited By ~ 1

Author(s):

H. Payne ◽

C. Battersby ◽

S. Hughes ◽

M. Taboada ◽

N.D. James

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Receptor Antagonist ◽

Phase Ii ◽

Phase Ii Trial ◽

Endothelin A Receptor ◽

Endothelin A ◽

Hormone Resistant Prostate Cancer

Role of Quality of Life in Men with Metastatic Hormone-Refractory Prostate Cancer: How Does Atrasentan Influence Quality of Life?

European Urology ◽

10.1016/j.eururo.2005.12.058 ◽

2006 ◽

Vol 49 (5) ◽

pp. 781-789 ◽

Cited By ~ 15

Author(s):

David Cella ◽

Daniel P. Petrylak ◽

Mayer Fishman ◽

Chris Teigland ◽

Jay Young ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-07-0944 ◽

2008 ◽

Vol 14 (9) ◽

pp. 2763-2767 ◽

Cited By ~ 149

Author(s):

Dominik R. Berthold ◽

Gregory R. Pond ◽

Martin Roessner ◽

Ronald de Wit ◽

Mario Eisenberger ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Prostate Specific Antigen ◽

Specific Antigen ◽

Phase II trial of weekly docetaxel, zoledronic acid and selenium for hormone refractory prostate cancer

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.16113 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 16113-16113

Author(s):

J. G. Kattan ◽

M. Ghosn ◽

G. Chahine ◽

A. Saroufim ◽

F. Nasr ◽

...

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Phase Ii ◽

Phase Ii Trial ◽

Weekly Docetaxel ◽

An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.14547 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 14547-14547 ◽

Cited By ~ 17

Author(s):

H. S. Pandha ◽

A. Protheroe ◽

J. Wylie ◽

C. Parker ◽

J. Chambers ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Open Label ◽

Open Label Phase ◽

Hormone Refractory ◽

Bi 2536

PHASE II TRIAL OF TESMILIFENE PLUS MITOXANTRONE AND PREDNISONE FOR HORMONE REFRACTORY PROSTATE CANCER: HIGH SUBJECTIVE AND OBJECTIVE RESPONSE IN PATIENTS WITH SYMPTOMATIC METASTASES

The Journal of Urology ◽

10.1097/01.ju.0000176799.63184.99 ◽

2005 ◽

Vol 174 (5) ◽

pp. 1808-1813 ◽

Cited By ~ 15

Author(s):

D. RAGHAVAN ◽

L.J. BRANDES ◽

K. KLAPP ◽

T. SNYDER ◽

E. STYLES ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Objective Response ◽

Efficacy of Epoetin Beta on Hemoglobin, Quality of Life, and Transfusion Needs in Patients with Anemia Due to Hormone-refractory Prostate Cancer - A Randomized Study

Scandinavian Journal of Urology and Nephrology ◽

10.1080/003655901750425864 ◽

2001 ◽

Vol 35 (4) ◽

pp. 288-294 ◽

Cited By ~ 47

Author(s):

J-E. Johansson, P. Wersäll, Y. Bran

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Randomized Study ◽

Epoetin Beta ◽

Weekly paclitaxel/estramustine phosphate plus carboplatin administered either weekly or every 4 weeks in the treatment of hormone refractory prostate cancer (HRPC): A randomized phase II trial of the Minnie Pearl Cancer Research Network

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.4659 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4659-4659

Author(s):

A. A. Meluch ◽

F. A. Greco ◽

H. A. Burris ◽

J. B. Erland ◽

R. A. Khan ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Research ◽

Phase Ii ◽

Phase Ii Trial ◽

Research Network ◽

Estramustine Phosphate ◽

Cancer Research Network ◽

Randomized Phase Ii ◽